{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:25:26Z","timestamp":1788330326750,"version":"build-2803163510"},"reference-count":29,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,1,2]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>The scale-up of tuberculosis (TB) preventive treatment (TPT) must be accelerated to achieve the targets set by the United Nations High-level Meeting on TB and the End TB Strategy. The scale-up of effective TPT is hampered by concerns about operational challenges to implement the existing tests for TB infection. New simpler tests could facilitate the scale-up of testing for TB infection. We present a framework for evaluation of new immunodiagnostic tests for the detection of TB infection, with an aim to facilitate their standardised evaluation and accelerate adoption into global and national policies and subsequent scale-up. The framework describes the principles to be considered when evaluating new tests for TB infection and provides guidance to manufacturers, researchers, regulators and other users on study designs, populations, reference standards, sample size calculation and data analysis and it is also aligned with the Global Strategy for TB Research and Innovation adopted by the World Health Assembly in 2020. In addition, we briefly describe technical issues that should be considered when evaluating new tests, including the safety for skin tests, costs incurred by patients and the health system, and operational characteristics.<\/jats:p>","DOI":"10.1183\/13993003.04078-2020","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T15:58:13Z","timestamp":1611244693000},"page":"2004078","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Framework for the evaluation of new tests for tuberculosis infection"],"prefix":"10.1183","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-4267","authenticated-orcid":false,"given":"Yohhei","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"den Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-1535","authenticated-orcid":false,"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Penn-Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ruhwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Oxlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kanchar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Korobitsyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Zignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Kasaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"2024102102174778000_58.2.2004078.1","unstructured":"World Health Organization (WHO) . Implementing the End TB Strategy: The Essentials. Geneva, WHO, 2015."},{"key":"2024102102174778000_58.2.2004078.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00214014"},{"key":"2024102102174778000_58.2.2004078.3","unstructured":"United Nations General Assembly. A\/RES\/73\/3 . Political declaration of the High-level Meeting of the General Assembly on the Fight Against Tuberculosis: resolution\/adopted by the General Assembly. New York, United Nations General Assembly, 2018. http:\/\/digitallibrary.un.org\/record\/1649568"},{"key":"2024102102174778000_58.2.2004078.4","unstructured":"World Health Organization . Global Tuberculosis Report 2020. Geneva, WHO, 2020. www.who.int\/publications\/i\/item\/9789240013131"},{"key":"2024102102174778000_58.2.2004078.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1405427"},{"key":"2024102102174778000_58.2.2004078.6","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO) . WHO Consolidated Guidelines on Tuberculosis: Module 1: Prevention: Tuberculosis Preventive Treatment. Geneva, WHO, 2020.","DOI":"10.30978\/TB2021-2-86"},{"key":"2024102102174778000_58.2.2004078.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70210-9"},{"key":"2024102102174778000_58.2.2004078.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2017.01.015"},{"key":"2024102102174778000_58.2.2004078.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00946-2018"},{"key":"2024102102174778000_58.2.2004078.10","unstructured":"World Health Organization (WHO) . Consensus Meeting Report: Development of a Target Product Profile (TPP) and a Framework for Evaluation for a Test for Predicting Progression from Tuberculosis Infection to Active Disease. Geneva, WHO, 2017."},{"key":"2024102102174778000_58.2.2004078.11","unstructured":"World Health Organization (WHO) . Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle-Income Countries Policy Statement. Geneva, WHO, 2011."},{"key":"2024102102174778000_58.2.2004078.12","first-page":"S65","article-title":"Sensitivity of a novel skin test with recombinant protein ESAT6-CFP10 in new cases of tuberculosis in children and adolescents","volume":"49","author":"Slogotskaya","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"2024102102174778000_58.2.2004078.13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cmi.2016.07.015","article-title":"Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial","volume":"22","author":"Li","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024102102174778000_58.2.2004078.14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)30436-2","article-title":"Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon \u03b3 release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial","volume":"5","author":"Ruhwald","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102102174778000_58.2.2004078.15","doi-asserted-by":"crossref","first-page":"e0204554","DOI":"10.1371\/journal.pone.0204554","article-title":"C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: a phase 3 trial","volume":"13","author":"Aggerbeck","year":"2018","journal-title":"PLoS One"},{"key":"2024102102174778000_58.2.2004078.16","unstructured":"World Health Organization . Framework for the Evaluation of New Tests for Tuberculosis Infection. Geneva, WHO, 2020."},{"key":"2024102102174778000_58.2.2004078.17","unstructured":"Hamada Y . State of the art: tests for latent TB infection. AIDS 2020 virtual pre-conference: Turning threats into opportunities: implementing and advancing quality TB services for people living with HIV during the COVID-19 pandemic and beyond. https:\/\/www.iasociety.org\/Web\/WebContent\/File\/TBHIV-2020-Programme-26Jun2020.pdf"},{"key":"2024102102174778000_58.2.2004078.18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00408-016-9872-5","article-title":"Interferon-gamma release assays for the diagnosis of tuberculosis: a systematic review and meta-analysis","volume":"194","author":"Lu","year":"2016","journal-title":"Lung"},{"key":"2024102102174778000_58.2.2004078.19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s15010-019-01285-7","article-title":"Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA","volume":"47","author":"Nasiri","year":"2019","journal-title":"Infection"},{"key":"2024102102174778000_58.2.2004078.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00510-2016"},{"key":"2024102102174778000_58.2.2004078.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01245-2015"},{"key":"2024102102174778000_58.2.2004078.22","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02029"},{"key":"2024102102174778000_58.2.2004078.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200811-1704OC"},{"key":"2024102102174778000_58.2.2004078.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.08.018"},{"key":"2024102102174778000_58.2.2004078.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4053"},{"key":"2024102102174778000_58.2.2004078.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.theriogenology.2010.01.003"},{"key":"2024102102174778000_58.2.2004078.27","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201310-378OC"},{"key":"2024102102174778000_58.2.2004078.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201704-0817OC"},{"key":"2024102102174778000_58.2.2004078.29","unstructured":"World Health Organization (WHO) . Technical Guidance Series for WHO Prequalification \u2013 Diagnostic Assessment: Establishing Stability of in vitro Diagnostic Medical Devices. Geneva, WHO, 2017."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.04078-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:46:52Z","timestamp":1740383212000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.04078-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,19]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1183\/13993003.04078-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.04078-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}